PeptideDB

Cefoselis Sulfate (FK-037) 122841-12-7

Cefoselis Sulfate (FK-037) 122841-12-7

CAS No.: 122841-12-7

Cefoselis (also known as FK 037 Sulfate) is a widely used beta-lactam antibiotic of the cephalosporin class. Cefoselis i
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Cefoselis (also known as FK 037 Sulfate) is a widely used beta-lactam antibiotic of the cephalosporin class. Cefoselis inhibits GABA-induced currents in a concentration-dependent manner with IC50 of 185 mM. Cefoselis possesses a superior antistaphylococcal activity on MSSA isolates to both other compounds being however equal active to Cefepime and Cefpirome on multiresistant enterobacteriaceae. Cefoselis is dose-dependently appeared in brain extracellular fluid in proportion to its blood level. Cefoselis, a new parenteral cephalosporin, is active against clinical isolates of both gram-positive and gram-negative aerobic bacteria.


Physicochemical Properties


Molecular Formula C19H24N8O10S3
Molecular Weight 620.64
Exact Mass 620.077
Elemental Analysis C, 36.77; H, 3.90; N, 18.05; O, 25.78; S, 15.50
CAS # 122841-12-7
Related CAS # Cefoselis;122841-10-5;Cefoselis hydrochloride;911212-25-4
PubChem CID 9830519
Appearance White to off-white solid powder
LogP 0.027
Hydrogen Bond Donor Count 7
Hydrogen Bond Acceptor Count 17
Rotatable Bond Count 9
Heavy Atom Count 40
Complexity 1100
Defined Atom Stereocenter Count 2
SMILES

S1C([H])([H])C(C([H])([H])N2C([H])=C([H])/C(=N\[H])/N2C([H])([H])C([H])([H])O[H])=C(C(=O)O[H])N2C([C@]([H])([C@@]12[H])N([H])C(/C(/C1=C([H])SC(N([H])[H])=N1)=N\OC([H])([H])[H])=O)=O.S(=O)(=O)(O[H])O[H]

InChi Key LZOLCSVRFKCSEM-ZQCAECPKSA-N
InChi Code

InChI=1S/C19H22N8O6S2.H2O4S/c1-33-24-12(10-8-35-19(21)22-10)15(29)23-13-16(30)27-14(18(31)32)9(7-34-17(13)27)6-25-3-2-11(20)26(25)4-5-28;1-5(2,3)4/h2-3,8,13,17,20,28H,4-7H2,1H3,(H2,21,22)(H,23,29)(H,31,32);(H2,1,2,3,4)/b20-11?,24-12-;/t13-,17-;/m1./s1
Chemical Name

(6R,7R)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-3-((2-(2-hydroxyethyl)-3-imino-2,3-dihydro-1H-pyrazol-1-yl)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid compound with sulfuric acid (1:1)
Synonyms

Cefoselis sulfate; Cefoselis (sulfate); FK 037; 6EY42207VS; Cefoselis sulfate (JAN);
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage.(2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture.
Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


Targets β-lactam
ln Vitro Cefoselis inhibits GABA-induced currents in a concentration-dependent manner with IC50 of 185 mM. Cefoselis possesses a superior antistaphylococcal activity on MSSA isolates to both other compounds being however equal active to Cefepime and Cefpirome on multiresistant enterobacteriaceae. Cefoselis is dose-dependently appeared in brain extracellular fluid in proportion to its blood level. Cefoselis, a new parenteral cephalosporin, is active against clinical isolates of both gram-positive and gram-negative aerobic bacteria.
ln Vivo
Cefoselis elicits a massive elevation of extracellular glutamate concentration in normal rats. Cefoselis (50 mg/animal)-induced convulsions are prevented by pretreatment with 5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), diazepam and phenobarbital (ED(50) values (mg/kg) of 0.78, 1.59 and 33.0, respectively), but not by carbamazepine or phenytoin.
Animal Protocol
50 mg/animal
Rats
References

[1]. Cefoselis, a beta-lactam antibiotic, easily penetrates the blood-brain barrier and causes seizure independently by glutamate release. J Neural Transm (Vienna). 2004 Dec;111(12):1523-35.

[2]. In vitro activities of cefoselis compared to β-lactams and other antibacterial agents aganst gram-positive and gram-negative clinical isolates. Chinese Journal of Infection and Chemotherapy, 2011. 4: p. 002.

[3]. King, A., L. Bethune, and I. Phillips, The Comparative In Vitro Activity of FK-037 (Cefoselis), a New Broad-Spectrum Cephalosporin. Clin Microbiol Infect, 1995. 1(1): p. 13-17.

Additional Infomation Cefoselis sulfate is an azaheterocycle sulfate salt. It is functionally related to a member of cefoselis.
See also: Cefoselis (annotation moved to).

Solubility Data


Solubility (In Vitro) Water : 5~14.29 mg/mL(~23.02 mM)
DMSO : 3~100 mg/mL ( 4.83~161.12 mM )
Solubility (In Vivo) Solubility in Formulation 1: ≥ 2.5 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.5 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

Solubility in Formulation 3: ≥ 2.5 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.5 mg/mL (4.03 mM)

Solubility in Formulation 5: 25 mg/mL (40.28 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.6112 mL 8.0562 mL 16.1124 mL
5 mM 0.3222 mL 1.6112 mL 3.2225 mL
10 mM 0.1611 mL 0.8056 mL 1.6112 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.